
Immunotherapy is receiving interest as an alternative or adjuvant approach to the treatment of many malignancies. The potential for immune modulation as a treatment of solid tumors is the focus of cancer researchers throughout the world. Though not a novel idea, increasing technological sophistication and continued advancement in the understanding of the immune system have increased the number of novel therapeutic approaches. In urology, BCG is an excellent example of how modulation of the immune system can be used to treat malignancy, and we are only now beginning to understand its immune mechanisms. Numerous other immunotherapeutic approaches have been and are being developed and evaluated. We provide a brief overview of immunology and its relation to tumor development and growth, and focus on some of the immunotherapeutic approaches to renal cell carcinoma, prostate adenocarcinoma, and transitional cell carcinoma of the bladder.
Immunity, Cellular, Urologic Neoplasms, Th2 Cells, Antibody Formation, Humans, Immunotherapy, Th1 Cells
Immunity, Cellular, Urologic Neoplasms, Th2 Cells, Antibody Formation, Humans, Immunotherapy, Th1 Cells
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 8 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
